Thermo Fisher posts Q3 beat as lab products unit outperforms

Thermo Fisher Scientific (TMO) gained in the premarket on Wednesday after the life sciences company reported better-than-expected financials for Q3 2026, thanks mainly to its Laboratory Products and Biopharma Services unit.

The Waltham, Massachusetts-based healthcare giant added $12.1B in revenue for the quarter, with ~9% YoY growth, beating consensus by $190M, as Laboratory Products and Biopharma Services generated $6.9B, up ~15% YoY. Analysts had projected it to add $6.6B in revenue for the quarter.

However, Thermo’s (TMO) Life Sciences Solutions and Specialty Diagnostics businesses trailed expectations, generating $2.7B and $1.1B to the topline with ~5% YoY growth and ~7% YoY decline, respectively, compared with $2.8B and $1.2B in the consensus.

“We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top and bottom lines" CEO Marc Casper said ahead of the conference call at 7:00 a.m. ET, when the company typically issues its guidance.

Thermo's (TMO) adjusted earnings per share, meanwhile, reached $6.68, topping the consensus by $0.28, as its adjusted operating income and adjusted operating margin stood at roughly $3.0B and ~25%, respectively, beating the analysts’ estimates of ~$2.9B and ~24%, respectively.